Böcker i Current Cancer Research-serien

It presents the basic concepts behind circulating tumor cells (CTCs), metastatic biology, and potential applications as to how CTCs can be used in diagnostic biomarkers. CTCs are cells that have detached from the primary tumor and circulate in the bloodstream.

Engineering and Physical Approaches to Cancer addresses the newest research at this interface between cancer biology and the physical sciences. Several chapters address the mechanobiology of collective and individual cell migration, including experimental, theoretical, and computational perspectives. Other chapters consider the crosstalk of biological, chemical, and physical cues in the tumor microenvironment, including the role of senescence, polyploid giant cells, TGF-beta, metabolism, and immune cells. Further, chapters focus on circulating tumor cells and metastatic colonization, highlighting both bioengineered models as well as diagnostic technologies. Further, this book features the work of emerging and diverse investigators in this field, who have already made impressive cross-disciplinary scientific contributions. This book is designed for a general audience, particularly researchers conversant in cancer biology but less familiar with engineering (and vice-versa). Thus, we envision that this book will be suitable for faculty, postdoctoral fellows, and advanced graduate students across medicine, biological sciences, and engineering. We also anticipate this book will be of interest to medical professionals and trainees, as well as researchers in the pharmaceutical and biomedical device industry.Describes physical aspects of cancer, including collective cell migration, the aberrant tumor microenvironment, circulating tumor cells, and metastatic colonization.First volume available on the topic of physical aspects of cancer

Lung cancer has seen a paradigm shift in disease treatment over the past few years, with major changes in the therapeutic drugs now available as well as in the overall management approach.  For targeted and immunotherapeutic approaches, understanding the biology of acquired resistance is a key strategy that has yielded productive advances in the subsequent treatment.  Future advances also include incorporating biomarker data obtained from solid and liquid biopsies, as well as combination of immunotherapy with radiotherapy and in special populations such patients with CNS involvement.

Lung cancer has seen a paradigm shift in disease treatment over the past few years, with major changes in the therapeutic drugs now available as well as in the overall management approach.

This book contextualizes translational research and provides an up to date progress report on therapies that are currently being targeted in lung cancer.

This volume provides an integrated account of our current understanding of the functions of D-type cyclins during development and tumorigenesis, with special emphasis on the kinase-independent functions of these proteins.

Other reviews present new information about the role of asbestos-related inflammation and genetic factors, including the role of inherited mutations of BAP1, in mesothelioma causation, as well as recent research about gene signatures, cell signaling, and epigenetic mechanisms in asbestos-related diseases.

This volume will detail the current state and perspectives of autophagy-based cancer therapy. Covering a wide range of topics, it will include an overview of autophagy as a therapeutic target in cancer, autophagy modulators as cancer therapeutic agents, implications of micro-RNA-regulated autophagy in cancer therapy, modulation of autophagy through targeting PI3 kinase in cancer therapy, targeting autophagy in cancer stem cells, and roles of autophagy in cancer immunotherapy. In addition, the volume will review applications of system biology and bioinformatics approaches to discovering cancer therapeutic targets in the autophagy regulatory network. The volume will be beneficial for a variety of basic and clinical scientists, including cancer biologists, autophagy researchers, pharmacologists, and clinical oncologists who wish to delve more deeply into this field of cancer research.This volume will be the first book to focus solely on autophagy as a target in cancer therapy. As well, it will comprehensively discuss the roles of autophagy in most currently available cancer treatments.

This volume will provide a contemporary account of advances in chemical carcinogenesis. It will describe major mechanisms of mutagenesis, affects on tumor suppressor genes and proto-oncogenes, and how cell-cycle check points can be by-passed by the "stealth-like" properties of chemical carcinogens.

This volume, a state-of-the-art review of early phase clinical trials for cancer immunotherapy, discusses biomarker selection, combinatorial strategies and their safety or toxicity, determination of Phase 2 dosing, endpoints in the setting of radiographic pseudoprogression, histology selection, and novel immunotherapeutics as they relate to early phase cancer immunotherapy.

This volume covers the most important areas of glioblastoma - surgical resection, molecular pathology, targeted therapies, cancer stem cells, the role of DNA methylation, targeted sequencing for personalized therapy, animal models and advances in pediatric glioblastoma.

This volume provides an integrated account of our current understanding of the functions of D-type cyclins during development and tumorigenesis, with special emphasis on the kinase-independent functions of these proteins.

This volume covers the most important areas of glioblastoma - surgical resection, molecular pathology, targeted therapies, cancer stem cells, the role of DNA methylation, targeted sequencing for personalized therapy, animal models and advances in pediatric glioblastoma.

Other reviews present new information about the role of asbestos-related inflammation and genetic factors, including the role of inherited mutations of BAP1, in mesothelioma causation, as well as recent research about gene signatures, cell signaling, and epigenetic mechanisms in asbestos-related diseases.

Squamous cell cancers of the head and neck (SCCHN), also known as head and neck cancers (HNC) encompass malignancies of the oral cavity, larynx, nasopharynx and pharynx, and are diagnosed in over 500,000 patients worldwide each year, accounting for 5% of all malignancies.

Squamous cell cancers of the head and neck (SCCHN), also known as head and neck cancers (HNC) encompass malignancies of the oral cavity, larynx, nasopharynx and pharynx, and are diagnosed in over 500,000 patients worldwide each year, accounting for 5% of all malignancies.